Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia
Jorge J. Castillo(Dana-Farber Cancer Institute), Steven P. Treon(Dana-Farber Cancer Institute), Zachary R. Hunter(Harvard University), John N. Allan(Cornell University), Ranjana H. Advani(Stanford Medicine), Andrew Keezer(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Joshua Gustine(Boston University), Kirsten Meid(Shaanxi Research Association for Women and Family), Toni Dubeau(Shaanxi Research Association for Women and Family), Guang Yang(Blueprint Medicines (United States)), Jessica Lam(Stanford University), Tanya Siddiqi(City Of Hope National Medical Center), Lian Xu(Huazhong Agricultural University), Richard R. Furman(Cornell University)
Cited by 38
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k